Owner Scorecard


← All companies ← GRAN Manual GROY → ← GRCE Pharmaceuticals GSK →

GRFS, Grifols S.A.

Pharmaceuticals consumer brand

Revenue is led by Biopharma (85%) and Diagnostic (9%), with 2 more segments behind.

Latest annual: FY2024 20-F · figures as filed, in EUR · 1 ADS = 1 ordinary share
GRFS · Grifols S.A.
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2024
€7.2B
+9.4% YoY · 7% 5-yr CAGR
Vital signs · TTM, with 5-yr average
Revenue €7.2B 5-yr avg €6.0B
Gross margin 39% 5-yr avg 39%
Operating margin 16.5% 5-yr avg 14.4%
ROIC 8% 5-yr avg 8%
Owner-earnings margin 9% 5-yr avg 5%
Free cash flow margin 9% 5-yr avg 5%

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

What it is
A pharmaceutical business, where patents grant a temporary monopoly the pipeline must keep refilling.
What moves the needle
Gross margin has run about 42% and operating margin about 19% through the cycle, a solid spread between what it charges and what the product costs to make. Inventory runs near 46% of sales, so how fast it turns back into cash — and the risk of writing it down when demand softens — sits alongside the margin. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on customer concentration, set against the numbers in what the filing emphasizes, below.
Is it a good business?
Return on capital has sat near the cost of capital (median 10%). By owner earnings: roughly 8% of revenue reaches owners as cash, though it swings. This is price-taker territory, where the balance sheet and the cycle matter more than any multiple; the rest is in the 10-K.

Every line is arithmetic on the company's filings, shown in full in the sections below.

Where the money comes from

read the 20-F →

Biopharma is 85% of revenue, with Diagnostic the other meaningful segment at 9%.

Revenue by reportable segment, FY2024
  • Biopharma85%€6.1B
  • Diagnostic9%€645M
  • Bio Supplies3%€216M
  • Others3%€208M
By geographyUSA and Canada57%Rest of the world23%Rest of European Union15%Spain6%

From the segment footnote of the company's own 20-F. Shares are of total revenue; the profit bar shows each segment's share of segment operating profit, before unallocated corporate costs.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2015–2024

realized figures from each filing · older years to the left
2015’152016’162017’172018’182019’192020’202021’212022’222023’232024’24TTMTTMDec 2024
Income statement
€3.9B€4.0B€4.3B€4.5B€5.1B€5.3B€4.9B€6.1B€6.6B€7.2B€7.2BRevenueRevenue
49%47%50%46%46%42%40%37%38%39%39%Gross marginGross mgn
€970M€939M€1.0B€994M€1.1B€996M€595M€782M€782M€1.2B€1.2BOperating incomeOp. inc.
24.7%23.2%23.2%22.2%22.2%18.7%12.1%12.9%11.9%16.5%16.5%Operating marginOp. mgn
€532M€545M€663M€597M€625M€619M€189M€185M€42M€157M€157MNet incomeNet inc.
23%24%5%18%21%22%31%33%51%60%60%Effective tax rateTax rate
Cash flow & returns
€743M€553M€842M€737M€569M€1.1B€597M(€1M)€219M€902M€902MOperating cash flowOp. cash
€190M€202M€215M€229M€302M€322M€360M€411M€446M€438M€438MDepreciationDeprec.
€21M(€194M)(€36M)(€88M)(€359M)€170M€48M(€597M)(€270M)€307M€307MWorking capital & otherWC & other
€523M€249M€252M€232M€310M€280M€247M€284M€224M€233M€233MCapexCapex
13.3%6.2%5.8%5.2%6.1%5.2%5.0%4.7%3.4%3.2%3.2%Capex / revenueCapex/rev
€553M€304M€590M€505M€259M€830M€350M(€285M)(€6M)€670M€670MOwner earningsOwner earn.
14.1%7.5%13.7%11.3%5.1%15.5%7.1%−4.7%−0.1%9.3%9.3%Owner earnings marginOE mgn
€220M€304M€590M€505M€259M€830M€350M(€285M)(€6M)€670M€670MFree cash flowFCF
5.6%7.5%13.7%11.3%5.1%15.5%7.1%−4.7%−0.1%9.3%9.3%Free cash flow marginFCF mgn
€222M€216M€218M€279M€239M€113M€259M€592K€0€962K€962KDividends paidDiv. paid
€58M€13M€126M€3M€0BuybacksBuybacks
12%10%12%10%6%6%8%8%ROICROIC
16%15%18%14%13%12%3%3%1%3%3%Return on equityROE
9%9%12%8%8%10%−1%3%1%3%3%Retained to equityRetained/eq
Balance sheet
€1.1B€898M€897M€1.1B€2.5B€580M€2.7B€549M€530M€980M€2.7BCash & investmentsCash+inv
€534M€386M€404M€491M€520M€500M€739M€767M€836M€836MReceivablesReceiv.
€1.6B€1.6B€1.9B€2.3B€2.0B€2.3B€3.2B€3.5B€3.6B€3.6BInventoryInvent.
€612M€572M€724M€753M€746M€785M€919M€971M€1.1B€1.1BAccounts payablePayables
€1.6B€1.4B€1.6B€2.1B€1.8B€2.0B€3.1B€3.3B€3.3B€3.3BOperating working capitalOper. WC
€3.1B€2.9B€3.5B€5.4B€3.2B€5.5B€4.7B€6.1B€5.7B€5.7BCurrent assetsCur. assets
€1.1B€978M€1.3B€1.4B€1.3B€3.5B€2.0B€2.3B€2.2B€2.2BCurrent liabilitiesCur. liab.
2.9×3.0×2.8×3.9×2.4×1.6×2.3×2.6×2.7×2.7×Current ratioCurr. ratio
€3.5B€3.6B€4.6B€5.2B€5.5B€5.3B€6.2B€7.0B€6.8B€7.4B€7.4BGoodwillGoodwill
€9.6B€10.1B€10.9B€12.5B€15.5B€15.3B€19.2B€21.2B€21.0B€21.4B€21.4BTotal assetsAssets
€5.0B€5.0B€3.5B€3.3B€3.6B€3.6B€3.6B€2.3B€2.3BTotal debtDebt
€4.1B€3.9B€1.0B€2.7B€903M€3.0B€3.1B€1.4B(€371M)Net debt / (cash)Net debt
4.0×3.8×3.8×3.4×3.3×4.0×2.2×1.6×1.3×1.7×1.7×Interest coverageInt. cov.
€3.3B€3.7B€3.6B€4.2B€4.8B€5.1B€5.5B€5.6B€5.4B€5.9B€5.9BShareholders’ equityEquity
Per share
684M683M684M685M685M686M682M680M680M680M680MShares out (diluted)Shares
€5.76€5.93€6.31€6.55€7.44€7.79€7.24€8.92€9.70€10.61€10.61Revenue / shareRev/sh
€0.78€0.80€0.97€0.87€0.91€0.90€0.28€0.27€0.06€0.23€0.23EPS (diluted)EPS
€0.81€0.44€0.86€0.74€0.38€1.21€0.51€-0.42€-0.01€0.99€0.99Owner earnings / shareOE/sh
€0.32€0.44€0.86€0.74€0.38€1.21€0.51€-0.42€-0.01€0.99€0.99Free cash flow / shareFCF/sh
€0.32€0.32€0.32€0.41€0.35€0.17€0.38€0.00€0.00€0.00€0.00Dividends / shareDiv/sh
€0.76€0.37€0.37€0.34€0.45€0.41€0.36€0.42€0.33€0.34€0.34Cap. spending / shareCapex/sh
€4.83€5.45€5.30€6.17€7.04€7.45€8.10€8.31€7.90€8.66€8.66Book value / shareBVPS
Per-share growththe realized rate an owner's share compounded
9-yr5-yr
Revenue / share+7.0%/yr+7.4%/yr
Owner earnings / share+2.2%/yr+21.2%/yr
EPS−12.6%/yr−24.0%/yr
Dividends / share−45.3%/yr−66.8%/yr
Capital spending / share−8.5%/yr−5.5%/yr
Book value / share+6.7%/yr+4.2%/yr

The record, charted

FY2015–2024

Each measure over its full record; the current point and the worst year marked.

Share count
680Mpeak FY2020
ROIC
8%low FY2022
Gross margin
39%low FY2022

Owner earnings vs. net income

Owner earningsNet income

The accountant's number, and the cash an owner can take; the gap is the tell.

€670Mowner earningsvs.€157Mnet incomelow FY2022

Where the cash went

ReinvestBuybacksDividendsAcquisitionsRetained

Each year's operating cash, by what management did with it: the mix, and how it drifts.

FY2015FY2024

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2024 the business turned €157M of profit into €670M of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.

Reported net income€157M
Owner earnings€670M · 9% of revenue
FY2024FY2023FY2022FY2021FY2020
Reported net income€157M€42M€185M€189M€619M
Depreciation & amortizationnon-cash charge added back+€438M+€446M+€411M+€360M+€322M
Working capital & othertiming of cash in and out, other non-cash items+€307M−€270M−€597M+€48M+€170M
Cash from operations€902M€219M(€1M)€597M€1.1B
Capital expenditurecash put back in to keep running and to grow−€233M−€224M−€284M−€247M−€280M
Owner earnings€670M(€6M)(€285M)€350M€830M
Owner-earnings marginowner earnings ÷ revenue9%0%-5%7%16%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2024 20-F · source on SEC EDGAR →
Material weakness in financial controls
“In the year ended December 31, 2024, we identified a material weakness related to the accounting for complex transactions during the preparation of the consolidated financial statements.”
Restated past financials
“This investment was originally recorded as equity, but was later restated as debt in our consolidated financial statements for the year ended December 31, 2021, prepared under pursuant to IFRS-EU and filed with the CNMV in Spain.”

The figures below are only as sound as the controls that produced them. read the note →

Will it survive?

  • Thin
    Operating income €1.2B ÷ interest expense €715M
    What this means

    Operating profit covers interest, but with little room. A bad year, a refinancing at higher rates, or a revenue wobble closes the gap fast.

  • Net cash
    Cash €980M + ST investments €1.7B − debt €2.3B
    What this means

    Cash and short-term investments exceed every dollar of debt by €371M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Long (60+ days)
    DSO 42 + DIO 294 − DPO 93 days
    What this means

    Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.

Is it a good business?

  • Solid through the cycle
    7-yr median, range 6%–12%; 8% latest = NOPAT €596M ÷ invested capital €7.2B
    Industry peers: median 2%
    What this means

    The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 7 years (it ran 8% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.

  • Solid through the cycle
    10-yr median margin, range -5%–16%; latest €670M = operating cash €902M − maintenance capex €233M
    Industry peers: median 12%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 9% of revenue this year, a 8% median across 10 years.

  • Cash-backed
    Cash from ops €902M ÷ net income €157M

    In the filing’s words The filing discloses a material weakness in its financial controls — the reported numbers here, and the record built on them, are only as reliable as the controls that produced them.

    What this means

    How much of reported profit showed up as operating cash. Above 1× is reassuring; well below suggests earnings lean on accruals. One year is noisy, growth and working-capital swings distort it, and this is operating cash, not free cash. Watch the multi-year trend.

How is the cash used?

  • Reinvests most of it
    Dividends + buybacks €962K ÷ Owner Earnings €670M
    What this means

    Of €670M Owner Earnings, €962K (0%) went back to shareholders, €962K dividends, €0 buybacks. Returning most of it is the mark of a mature business with little left to reinvest at a high return; reinvesting most could mean a long runway, or empire-building. The split doesn't say which; the return earned on it (see ROIC) does.

  • Investing or harvesting? 0.53×
    Harvesting
    Capex €233M ÷ depreciation €438M
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

Graham’s defensive tests · 3 of 5 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size
    Revenue ≥ $2B (a dollar floor) · €7.2B
    What this means

    Big enough to weather a storm. Graham's floor is a dollar figure — about $2B of revenue as a conservative modern stand-in. This company reports in its home currency and we carry no exchange rate, so we show the figure and leave the size bar for you to apply rather than convert it with a number we don't have.

  • Strong liquidity Pass
    Current ratio ≥ 2× · 2.66×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Conservative debt Pass
    Debt ≤ working capital · €2.3B vs €3.6B WC
    What this means

    Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.

  • Earnings stability Pass
    A profit every year (10-yr record) · no losses
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record Near
    Uninterrupted dividends · 9 of 10 yrs
    What this means

    An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.

  • Earnings growth Miss
    Earnings +33% over the record · −78%
    What this means

    At least a third more earnings than a decade ago, averaging three years at each end. Net income (not per-share), so stock splits don't distort it, buybacks and dilution show up in the share-count line instead.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are €0.19/share (latest year €0.23), the averaged base the calculator's gate runs on, and book value is €8.66/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2015–2024

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 10 of 10
    What this means

    Never lost money over the record, the earnings stability Graham insisted on.

  • Return on capital ≥ 15% 0 of 8 yrs
    What this means

    A moat shows up as a high return on invested capital that holds year after year, not one good vintage.

  • Operating margin 24% → 14% (3-yr avg ends)

    In the filing’s words The filing attributes gains to higher prices but names price competition too — and the margin slipped, so the pressure is winning here.

    What this means

    Through the cycle the operating margin slipped — about 24% early to 14% lately, median 19% — competition or costs are biting in.

  • Reinvestment, incremental ROIC returns capital
    What this means

    The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.

  • Owner earnings growth −3%/yr
    What this means

    Owner earnings shrank about 3% a year over the record.

  • Worst year 2023 · 11.9% op. margin
    What this means

    Stayed profitable even in its hardest year, the resilience that survives recessions.

  • Share count −0.1%/yr
    What this means

    Roughly flat share count, little dilution, little buyback.

  • Dividend record paid
    What this means

    Paid a dividend in 9 of the years on record.

Does AI threaten the moat?

Low contestability

The moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.

In its own filing Named as a competitive risk

Its FY2025 10-K names artificial intelligence as a competitive threat.

“Our Diagnostics Research & Development team continues to evaluate new technologies and research tools, including artificial intelligence (AI), to assess their potential for improving our competitive advantage and for integration into our development portfolio.”

AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat, and the company is using it that way.

Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.

All figures as filed; the source filing is linked above.

Current Position

as of fiscal year-end, Dec 31, 2024

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets€5.7B
  • Cash & short-term investments€2.7B
  • Receivables€836M
  • Inventory€3.6B
Current liabilities€2.2B
  • Accounts payable€1.1B
  • Other current liabilities€1.0B
Current ratio2.66×all current assets ÷ what's due · Graham looked for 2×
Quick ratio1.01×stricter: inventory excluded
Cash ratio1.26×strictest: cash alone against what's due
Working capital€3.6Bthe cushion left after near-term bills
Deeper floors
Tangible book value(€4.4B)equity stripped of goodwill & intangibles
Net current asset value(€7.1B)Graham's net-net: current assets less all liabilities
Debt incl. operating leases€3.5B€1.1B of it operating leases

From the company's latest filing.

How the cash was used, 2015–2024

Over the record, the business generated €6.3B of operating cash; how management split it reads as a balanced allocator, splitting cash between the business, owners, and the balance sheet.

  • Reinvested€2.8B · 45%
  • Dividends€1.5B · 25%
  • Buybacks€200M · 3%
  • Retained (debt / cash)€1.7B · 27%
  • Returned to owners€1.7B

    46% of the owner earnings the business produced over the span, €1.5B as dividends and €200M as buybacks.

  • Source of fundingOperating cash

    Operating cash covered reinvestment and returns; over the span cash and short-term investments rose €1.6B.

  • Average price paid for buybacks

    Buybacks ran €200M over the span, but the filings don't tag the share count needed to deduce the average price paid.

  • Net change in share count−0.6%

    The diluted count barely moved (684M to 680M): buybacks roughly offset the stock issued to staff.

  • Dividend record€0.00/sh

    Paid in 9 of the years on record, the per-share dividend shrinking about 45% a year. It was cut at least once along the way.

  • Return on what it retained−15%

    Of the earnings it kept rather than paid out (€2.4B over the span), annual owner earnings (first three years vs last three) fell €356M, so each retained €1 gave back about 0.15 of yearly owner earnings. Buffett's test, run on owner earnings instead of market value.

Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.

Acquisitions & goodwill

from the balance sheet & the 10-year cash-flow record

Goodwill grows only when a company acquires and falls only when it concedes it overpaid. The size of that bet, the cash put into buying rather than building, and how much has already been written off.

Goodwill & intangibles€10.3B48% of all assets; the premium carried on the balance sheet for businesses acquired
Against book equityexceeds itgoodwill alone is larger than the company’s entire book equity; stripped of the acquisition premium, there is no net book worth
Cash spent acquiring€0over 10 years buying other businesses, against €2.8B of capital spent building

None written down over the record; the goodwill is still carried at full cost. That is the deals holding their value on the books so far; whether they keep doing so is the test an owner watches, since the write-down, when it comes, is the admission the price was too high.

Goodwill, acquired intangibles and equity from the latest balance sheet; acquisition spend and write-downs summed across the 10-year record, from the company's own filings.

Inverting the record

Invert: instead of why Grifols S.A. is a good business, the question is what would make owning it a mistake, and whether those marks are in the record. Disconfirming tests across 2015–2024.

1 of the 3 tests turned up something to look into; the other 2 came back clean.

  • Look hereIs it less profitable than it was?1.5% vs 11.7%

    The owner-earnings margin averaged 11.7% early in the record and 1.5% across the last three years, and the latest year has not recovered. Ask the filing whether that is a structural drift or a cyclical trough — price, mix, cost, or a competitor — and whether it is permanent.

And these came back clean
  • Did the share count rise anyway?
  • Did reported profit become cash?

Each test is read from the filings and is noisy alone; a flag can mark a cyclical trough or a year of heavy investment as easily as a problem. The filing says which.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.

CompanyRevenueGross marginOp. marginROICOwner earn. margin
VRTXVertex Pharmaceuticals Incorporated$12.0B87%31.8%36%34%
BHCBausch Health Companies Inc.$10.3B76%5.5%2%13%
ZTSZoetis Inc.$9.5B69%34.2%26%22%
GRFSGrifols S.A.€7.2B44%20.4%10%8%
OGNOrganon$6.2B62%25.0%17%12%
ONCBeOne Medicines Ltd.$5.3B86%-124.4%-46%-112%
ELANElanco Animal Health Incorporated$4.7B54%-3.2%-1%4%
PRGOPerrigo Company plc$4.3B36%3.9%1%6%
Group median66%12.9%6%10%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Enter the US price, in dollars: the NYSE/Nasdaq quote you hold. Per the filing's own cover, “American Depositary Shares evidenced by American Depositary Receipts, each American Depositary Share representing one Class”; Grifols S.A. reports in EUR, so every figure in this tool is stated per ADS and translated at EUR 1 = $1.145 (2026-07-17, reference rate) so your dollar quote reconciles exactly. The record tables elsewhere on this page remain as filed, in EUR.

Type today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Grifols S.A. has delivered.

$

Through the cycle, Grifols S.A. earns about $693M on its 8.4% median owner-earnings margin. This year’s 9.3% margin runs in line with that. Normalize, below, values the price on that through-cycle figure rather than the latest year.

Base

The assumptions

9.0% = the 4.55% 10-year Treasury (Jul 15, 2026) + 4.45 points of equity premium. The rate you require is yours to set.

Enter a price above to run it.

Implied by the price
Owner-earnings growth · ’20→’24−13%/yr
Owner-earnings growth · ’15→’24+3%/yr
Owner-earnings yield
P/E (3-yr earnings ’22–’24)
P/B
Graham’s price gate

Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.

Against a high-grade bond: Graham’s yardstick bond yield%

Prefilled with the 10-year Treasury (4.55%, as of Jul 15, 2026). Edit it for today’s exact figure, or a AAA corporate yield.

Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.

Owner earnings $767M on 680M shares outstanding (a weighted average, the only count this filer tags); net cash $424M. The base is the latest year by default; Normalize values it on the through-cycle median owner-earnings margin (to avoid paying on a peak year). Net of stock comp treats option pay as the expense it is. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.

Cite: Owner Scorecard, "Grifols S.A. (GRFS), the owner's record," https://ownerscorecard.com/c/GRFS, data as of 2026-07-09.

Manual order: ← GRAN its page in the Manual GROY →

Industry order: ← GRCE the Pharmaceuticals chapter GSK →